论文部分内容阅读
应用逆转录多聚酶链式反应（ＲＴ－ＰＣＲ）技术，定量检测了６８例胃癌，５８例大肠癌组织中多药耐药基因（ＭＤＲ１）的表达水平，并对１１例胃癌及大肠癌患者进行了追踪检测。结果表明：化疗后肿瘤组织细胞中ＭＤＲ１的表达量（＞０．５）明显高于化疗前（＜０．５），ＭＤＲ１的表达量化疗后与化疗前比较差异显著（Ｐ＜０．０１），而且随化疗疗程数的增加，ＭＤＲ１表达量有上升的趋势。患者化疗效果与ＭＤＲ１的表达密切相关，与ＭＤＲ１的表达量成反比。ＭＤＲ１的表达可成为临床医生监测病情、选择有效的化疗药物、判断预后的重要参考指标。此法以临床标本为样品直接进行检测，以ＭＤＲ１／β２Ｍ为ＭＤＲ１的表达量，排除了实验过程中诸多因素的干扰，使样本之间的比较更加合理，结果准确、可信。
Reverse transcriptase polymerase chain reaction (RT-PCR) was used to quantitatively detect the expression of multidrug resistance gene (MDR1) in 68 cases of gastric cancer and 58 cases of colorectal cancer, and 11 cases of gastric cancer and colorectal cancer were examined. Tracking test. The results showed that the expression of MDR1 in tumor cells after chemotherapy (>0.5) was significantly higher than before chemotherapy (<0.5), and the expression of MDR1 after chemotherapy was significantly different from that before chemotherapy (P<0.01). , And with the increase in the number of chemotherapy treatment, MDR1 expression has an increasing trend. The effect of chemotherapy in patients is closely related to the expression of MDR1 and inversely proportional to the expression of MDR1. The expression of MDR1 can be an important reference index for clinicians to monitor the condition, select effective chemotherapy drugs and judge prognosis. This method uses the clinical specimen as a sample for direct detection. MDR1/β2M is used as the expression of MDR1, which excludes the interference of many factors during the experiment and makes the comparison between the samples more reasonable. The result is accurate and credible.